Jill Donaldson, APRN
Psychiatric/Mental Health · Great Falls, MTNPI 1497293864
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 157 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 19.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $879, 3.9 times the $225 reported in 2021. Among psychiatric/mental health clinicians in MT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 157 payments — averaging $16.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$508
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$359
- AbbVie$349
- Teva Pharmaceuticals USA, Inc.$299
- Neurocrine Biosciences, Inc.$239
- Johnson & Johnson$210
- plus $589 from 10 others
What the payments were for
- Food & beverage$2,554100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 31 | $508 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 24 | $359 |
| AbbVie | 24 | $349 |
| Teva Pharmaceuticals USA, Inc. | 18 | $299 |
| Neurocrine Biosciences, Inc. | 12 | $239 |
| Johnson & Johnson | 12 | $210 |
| Sunovion Pharmaceuticals Inc. | 11 | $115 |
| Lundbeck LLC | 6 | $111 |
| Alkermes, Inc. | 5 | $96 |
| Vanda Pharmaceuticals Inc. | 4 | $81 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $56 |
| Indivior Inc. | 2 | $40 |
| E.r. Squibb & Sons, L.L.C. | 2 | $34 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| Eisai Inc. | 1 | $18 |
| Sage Therapeutics, LLC | 1 | $17 |
How this compares
$2,554 in reported general payments places this provider in the 95th percentile of 142 psychiatric/mental health providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 12 | $40,224 |
| VraylarCariprazine Hcl | 24 | $31,507 |
| Lurasidone Hcl | 80 | $20,918 |
| VivitrolNaltrexone Microspheres | 11 | $18,052 |
| TrintellixVortioxetine Hydrobromide | 30 | $14,125 |
| Aripiprazole | 101 | $6,718 |
| Paliperidone ErPaliperidone | 19 | $5,187 |
| VyvanseLisdexamfetamine Dimesylate | 12 | $4,421 |
| Divalproex Sodium ErDivalproex Sodium | 63 | $2,602 |
| Olanzapine | 98 | $2,313 |
| Quetiapine Fumarate | 188 | $2,292 |
| Lamotrigine | 231 | $2,272 |
| Trazodone Hcl | 248 | $2,168 |
| SeroquelQuetiapine Fumarate | 11 | $2,162 |
| Duloxetine Hcl | 125 | $2,004 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $210 | $40,22412 claims |
| AbbVieVraylar | $349 | $31,50724 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $56 | $18,54642 claims |
| Alkermes, Inc.Vivitrol | $96 | $18,05211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 142 psychiatric/mental health providers in Montana.
Other psychiatric/mental health in Great Falls
- William BowdenGreat Falls$2K
- Karlee HamiltonGreat Falls$1K
- Shelley AndrusGreat Falls$1K
- David JanschGreat Falls$752
- Sara ReynoldsGreat Falls$262
- Tommie PerusichButte$4K
- Heather BrownKalispell$3K
- Sherry MartinMissoula$3K
- Jennifer DurwardHavre$2K
- Susan FinnBillings$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.